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Background: Based on report of declining efficacy of chloroquine, Ghana shifted to the use of artemisinin-based
combination therapy (ACT) in 2005 as the first-line anti-malarial drug. Since then, there has not been any major
evaluation of the efficacy of anti-malarial drugs in Ghana in vitro. The sensitivity of Ghanaian Plasmodium falciparum
isolates to anti-malarial drugs was, therefore, assessed and the data compared with that obtained prior to the
change in the malaria treatment policy.
Methods: A SYBR Green 1 fluorescent-based in vitro drug sensitivity assay was used to assess the susceptibility of
clinical isolates of P. falciparum to a panel of 12 anti-malarial drugs in three distinct eco-epidemiological zones in
Ghana. The isolates were obtained from children visiting health facilities in sentinel sites located in Hohoe,
Navrongo and Cape Coast municipalities. The concentration of anti-malarial drug inhibiting parasite growth
by 50% (IC50) for each drug was estimated using the online program, ICEstimator.
Results: Pooled results from all the sentinel sites indicated geometric mean IC50 values of 1.60, 3.80, 4.00,
4.56, 5.20, 6.11, 10.12, 28.32, 31.56, 93.60, 107.20, and 8952.50 nM for atovaquone, artesunate, dihydroartemisin,
artemether, lumefantrine, amodiaquine, mefloquine, piperaquine, chloroquine, tafenoquine, quinine, and
doxycycline, respectively. With reference to the literature threshold value indicative of resistance, the parasites
showed resistance to all the test drugs except the artemisinin derivatives, atovaquone and to a lesser extent,
lumefantrine. There was nearly a two-fold decrease in the IC50 value determined for chloroquine in this study
compared to that determined in 2004 (57.56 nM). This observation is important, since it suggests a significant
improvement in the efficacy of chloroquine, probably as a direct consequence of reduced drug pressure after
cessation of its use. Compared to that measured prior to the change in treatment policy, significant elevation
of artesunate IC50 value was observed. The results also suggest the existence of possible cross-resistance
among some of the test drugs.
Conclusion: Ghanaian P. falciparum isolates, to some extent, have become susceptible to chloroquine in vitro,
however the increasing trend in artesunate IC50 value observed should be of concern. Continuous monitoring
of ACT in Ghana is recommended.
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Malaria, caused by an infection with Plasmodium falcip-
arum, is complex and affects a significant number of
people living in disease-endemic areas of the world, es-
pecially sub-Saharan Africa. According to the World
Health Organization (WHO) World Malaria Report,
there were about 219 million cases of malaria in 2010
and an estimated 660,000 deaths [1]. Most of these cases
occur among children within whom the disease can
sometimes present in a severe form, often with devastat-
ing consequences. Countries in sub-Saharan Africa, com-
prising some of the poorly developed nations in the world,
bear a major part of the disease burden with at least 90%
of the reported deaths [1,2].
In Ghana, malaria is hyper-endemic and remains the
most widely diagnosed infectious disease in the country.
It is the single most important cause of mortality and
morbidity especially among children under five years
and pregnant women [3]. The disease is responsible for
up to 40% of daily outpatient consultations at hospitals
and clinics across the country, accounting for over 23%
of deaths among children below the age of five years
[4-6]. Early presumptive treatment of febrile illness with
chloroquine was the mainstay of malaria control in
Ghana until 2005 when there was strong indication of
P. falciparum resistance to this drug. Reports from
drug efficacy study conducted in the country provided
strong evidence of the existence of P. falciparum iso-
lates that were resistant to chloroquine [7]. Based on
this evidence and upon the recommendation of the
WHO among others, in 2005 Ghana officially changed
from the use of chloroquine to artemisinin-based com-
bination therapy (ACT) as the first choice of anti-
malarial drugs for the treatment of uncomplicated
malaria. At the moment, ACT recommended by the
national malaria control programme (NMCP) of Ghana
is artesunate–amodiaquine (AA), with artemether-
lumefantrine (AL) and dihydoartemisinin-piperaquine
(DHAP) as alternatives. It must be emphasized that in
the absence of either an effective vaccine or good alter-
native anti-malarial drugs to ACT, the emergence and
spread of artemisinin-resistant parasites would be dev-
astating. Although no resistance to combination ther-
apy has yet been reported in Ghana, it is important
that these drugs are closely monitored for early detec-
tion of reduced parasite susceptibility, especially as re-
ports have appeared of P. falciparum isolates with
decreased response to artemisinin in other parts of the
world [8].
In vitro test of P. falciparum susceptibility to anti-
malarial drugs is one of the important tools that can be
used to monitor the efficacy of anti-malarial drugs, as re-
sults of parasite responses to drugs may show early
trends in changes to susceptibility to the tested drugsand may serve as an early warning system of resistance
development in the parasite population [9]. Although
in vivo drug efficacy studies remain the ‘gold standard’
for assessment of anti-malarial drug resistance, its use is
limited because it is prohibitively expensive [10]. Mo-
lecular marker determination can also be used to iden-
tify the single-nucleotide polymorphisms commonly
associated with drug resistance in malaria parasites;
however, the methods require specialized equipment,
which are costly and the assay is difficult to conduct in
the field in real time [11]. Additionally, these markers
are not well described for the artemisinins. With the
low cost involved in carrying out the assay and the
rapidity with which it could be conducted, the in vitro
drug sensitivity test has become a strong choice for
assessing anti-malarial drug efficacy in disease-endemic
areas. The test is not affected by host-confounding factors
such as immunity, compliance, concomitant infections,
re-infection/recrudescence, poor drug absorption, etc.
[12,13]. The recently described SYBR Green 1 in vitro
assay for assessment makes performing the assay easier
and precise [14].
Since Ghana officially changed its malaria treatment
policy in 2005, there has been no major nationwide
in vitro assessment of parasites responses to anti-malarial
drugs. In order to determine if the change in policy has
significantly affected the susceptibility of the parasites to
anti-malarial drugs, this study was carried out to measure
the responses of clinical isolates of P. falciparum to anti-
malarial drugs and compare the outcome with baseline
data generated from a similar survey conducted in 2004
[15]. The in vitro susceptibility of P. falciparum iso-
lates to a panel of anti-malarial drugs was assessed
using the newly developed SYBR Green 1-fluorescent-
based method. The panel of 12 anti-malarials includes
the nationally recommended anti-malarial drugs for
treatment of uncomplicated malaria in Ghana, drugs
used for malaria prevention in travellers, and the pre-
vious first-line drug in the country, chloroquine. Cross-
resistance between drugs from the same chemical class or
between drugs with similar modes of action, and correla-
tions between susceptibility to different drug classes were
also determined and discussed.
Methods
Study sites
Three sentinel sites, Cape Coast, Hohoe and Navrongo,
representing three distinct eco-epidemiological zones in
Ghana were selected for the study (Figure 1). Cape Coast
(5°.07’N, 1°.11’W) is the capital of the Central region of
Ghana. It has a coastline of about 13 km and is about
150 km west of Accra (the capital city of Ghana). Vege-
tation in this area is mainly coastal savannah. Generally,
there are two rainy seasons in this region with the peak
Figure 1 Map of Ghana. A map of Ghana showing the sentinel sites used for the study. The sites are located in three unique ecological zones
in Ghana namely Coastal savannah (Cape Coast), Forest (Hohoe) and Guinea savannah (Navrongo). All sites are high transmission areas, but differ
from each other in the seasonal variation in malaria rates.
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and streams in this area end up in a lagoon, creating a
vast wetland. The presence of these water bodies allows
vector breeding throughout the year, hence malaria
transmission in this area is perennial. Hohoe (7º99N,
0°289E) is the capital of Hohoe municipality and lies in
the middle belt of the country, about 220 km north east
of Accra. This area with a vegetation of semi-deciduous
forest has two rainy seasons a year, the major one occur-
ring in May-June. Malaria transmission in this site is
perennial with a moderate seasonal peak occurring after
the major rains in June. Navrongo (10°549N, 1°69W), is
the capital of Kassena-Nankana district. It is about
865 km north of Accra and lies in the Guinea savannah
area in the Upper East region of Ghana. It receives all ofits annual rainfall between May and October. The pres-
ence of a large reservoir in the district, created to irri-
gate the land for farming, allows mosquitoes to breed
throughout the year. As a result, malaria is perennial but
with marked seasonal peak transmission occurring be-
tween June and November each year.
Study population and recruitment
During the main malaria seasons in 2012, children aged
six months to nine years presenting to clinics at the
study sites with fever or history of fever within the previ-
ous 24 hours were screened for inclusion in the investi-
gation. To be included in the study the child had to have
documented P. falciparum mono-infection at a count
ranging between 1,000 and 250,000 per μl. Detailed
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ents or guardians of potential participants and they were
encouraged to ask questions about any aspect of the
study that was unclear to them. A child was only en-
rolled if the parents or guardians gave their informed
consent. Sixty-three (63) patients were recruited from
each of the three sites to participate in the study. Per-
mission to carry out this work and ethical clearance
were obtained from the Institutional Review Board (IRB)
of the Noguchi Memorial Institute for Medical Research
(NMIMR), Ghana. This study also received ethical ap-
proval from the US Naval Medical Research Unit No. 3
(NAMRU-3) IRB, Cairo, Egypt.
Sample collection
Prior to treatment, 2 ml of blood were aseptically col-
lected from each participant into a tube containing cit-
rate phosphate dextrose-adenine (CPD-Adenine) and
transported to the laboratory for the in vitro drug test
within 24 hours. The blood was diluted 20× with complete
RPMI 1640 (Gibco, UK) and used for the assay.
In vitro test of susceptibility of Plasmodium falciparum to
anti-malarial drugs
Preparation of media, drugs dilutions and test plates
Incomplete RPMI 1640 culture media supplemented with
hypoxanthine and glucose were prepared as previously de-
scribed [14]. Complete RPMI 1640 contains NaHCO3 and
Albumax (Invitrogen). All drugs used in this study were
supplied by the World Wide Antimalarial Resistance Net-
work (WWARN), Centers for Disease Control and Pre-
vention (CDC), USA and Walter Reed Army Institute of
Research (WRAIR), Kisumu, Kenya. The panel of 12 drugs
tested in this study included: amodiaquine, artesunate,
artemether, atovaquone, chloroquine, dihydroartemisi-
nin, doxycycline, lumefantrine, mefloquine, piperaquine,
quinine, and tafenoquine. Five ml of stock solutions at
1 mg/ml were prepared for each anti-malarial drug. Amo-
diaquine, quinine, mefloquine, and artemisinin were dis-
solved in 70% ethanol and lumefantrine and doxycycline
in 100% dimethyl sulphoxide (DMSO). Chloroquine was
first dissolved in 1.5 ml deionized water after which the
solution was made up to 5 ml with absolute ethanol. The
drug solutions prepared were used immediately or stored
at −80°C for not longer than one month before use. Stock
solutions were further diluted in complete RPMI 1640 to
the desired starting concentrations after which two-fold
serial dilution was performed in 96-well tissue culture
plate to generate ten concentrations for the in vitro drug
test. The concentration range for the drugs (ng/ml) and
molecular weights (g/mol), which was later used to con-
vert to nM of the test drug concentration were, respect-
ively: amodiaquine (0.78-200 ng/ml, 464.51), artesunate
(0.78-200 ng/ml, 384.4), artemether (0.78-200 ng/ml,298.37), atovaquone (0.195-50 ng/ml, 366.84), chloro-
quine (7.8-2,000 ng/ml, 515.86), dihydroartemisinin
(0.78-200 ng/ml, 284.35), doxycycline (390.6-100,000 ng/ml,
512.94), lumefantrine (0.78-200 ng/ml, 528.94), mefloquine
(1.9-500 ng/ml, 414.77), piperaquine (15.6-4,000 ng/ml,
999.55), quinine (15.6-4,000 ng/ml, 321.41) and tafenoquine
(19.5-5,000 ng/ml, 463.49). Once pre-dosed with the anti-
malarial drugs, the plates were kept at 4°C until use. Test
plates were used within three days after preparation.Drug sensitivity testing
Two ml of blood collected from the patients was diluted
20× with complete RPMI 1640 and 100 μl was added to
each well of the pre-dosed test plate, starting with the
lowest concentration of drug and then progressively to
higher ones. Wells containing no drug but the diluted
patient’s blood was included on each plate. The plate
was placed in a modular incubator chamber and gassed
(gas contains 92.5% N2, 5.5% CO2, 2% O2). The chamber
was placed in an incubator set at 37ºC for 72 hours. La-
boratory reference clones, 3D7, regarded as chloroquine
sensitive and DD2 classified as chloroquine resistant,
were assayed periodically as internal control.
Assessment of the outcome of the in vitro drug test
was done using the SYBR Green1 method previously de-
scribed by Johnson and colleagues [14]. In brief, after
72 hours of incubation, the test plate was removed and
100 μl Malaria SYBR Green 1 fluorescent (MSF) lysis
buffer containing SYBR Green was added to each well
and mixed thoroughly by gently tapping on the plate.
The plate was covered with aluminium foil and incu-
bated at room temperature in the dark for at least two
hours. Fluorescence was then read on the prototype mi-
cro titer plate reader (MTPR) (QIAGEN).Data analysis
The concentration of anti-malarial drug inhibiting para-
site growth by 50% (IC50) for each drug was estimated
from a dose response curve by non-linear regression
analysis using an online program [16] previously de-
scribed by the groups of Le Nagard and Kaddouri
[17,18]. The program generated IC50 estimates with as-
sociated 95% confidence intervals (CI). Estimated values
with insufficient precision based on the CI were dis-
carded. Geometric mean (GM) IC50 was calculated for
each drug per sentinel site and a pooled national GM
IC50 valued was also determined. The use of GM was to
minimize the effects of outlier values. In order to check
for evidence of cross resistance, a Spearman’s Rank
Order correlation was run to determine the relationship
between drugs with similar modes of action or for those
belonging to the same chemical class. A p-value of 0.05
was considered indicative of a statistically significant
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present some of the results.
Results
Majority of the children clinically diagnosed with mal-
aria and confirmed by microscopy to have an infection
with P. falciparum qualified to participate in the study.
Sixty three clinical isolates were collected within one
month per site. Over 85% of the 189 P. falciparum clin-
ical isolates collected from the three selected sentinel
sites were successfully cultured and their susceptibilities
to the test anti-malarial drugs determined.
The outcome of the test of susceptibilities of clinical
isolates of P. falciparum collected from three sentinel
sites in Ghana is shown in Additional file 1: Table S1.
When the values for all the study sites were pooled, the
GM IC50 values determined for the country were 1.60,
3.80, 4.00, 4.56, 5.20, 6.11, 10.12, 28.32, 31.56, 93.60,
107.20, and 8952.50 nM for atovaquone, artesunate,
dihydroartemisin, artemether, lumefantrine, amodiaquine,
mefloquine, piperaquine, chloroquine, tafenoquine, quin-
ine, and doxycycline, respectively. Extremely high IC50
values were observed for some of the anti-malarial drugs;
for example, values of 1441.8 nM, 109.4 μM, 125.9 nM
and 6381.9 nM which are far above the threshold IC50
values discriminative for resistance were measured for
chloroquine, doxycycline, mefloquine, and quinine, re-
spectively. Generally, the isolates from Cape Coast ap-
peared to exhibit higher IC50 values to most of the drugs
compared to those from the other sites.
A snapshot of a scatter plot of IC50 values for six of
the popular anti-malarial drugs used in Ghana is shown
in Figure 2 (a-e). The percentage of the isolates that were
resistant for each of the anti-malarial drugs tested per
site based on published threshold IC50 values discrim-
inative for resistance is also shown in Additional file 1:
Table S1. The literature IC50 cut-off value indicative of
resistance used in this study were chloroquine, 100 nM
[19-21]; mefloquine, 30 nM [19,21,22]; amodiaquine, 80
nM [20-22]; lumefantrine, 150 nM [21,23]; doxycycline,
35 μM [21]; artesunate, 20 nM [21]; quinine, 800 nM
[20,22]; dihydroartemisinin, 12 nM [21] and artemether,
30 nM [21,24]. Cut-off resistant values for piperaquine
and tafenoquine were not available in the literature. It is
worth noting that prior to the emergence of atovaquone
resistance, Gay and colleagues published a cut-off value
of 5–7 nM for resistance [25]. However, upon the emer-
gence of P. falciparum resistance to atovaquone, the
group of Musset revised the cut-off to 1,900 nM after
investigations using resistant phenotype [26]. For the
drugs with known literature threshold IC50 values indi-
cative of resistance, the determined levels of resistance
recorded in this study were 13.5, 16.6, 3.7, 0.7, 23.7, 0,
7.1, 0, 0, and 0% for chloroquine, mefloquine, amodiaquine,lumefantrine, doxycycline, artesunate, quinine, dihydroarte-
misinin, artemether, and atovaquone, respectively.
Although the radio-isotopic method was used in deter-
mining the cut-off values indicative of resistance, it must
be emphasised that the IC50 values generated with the
Sybr Green 1fluorescence method is reported to be com-
parable. Smilkstein and co-workers reported that the
IC50 of standard anti-malarial drugs determined with
both radio-isotopic and Sybr Green methods were simi-
lar or identical [27]. Although the group of Johnson also
reported a similar observation, however the group ad-
mitted that a statistically significant difference exist be-
tween IC50 values generated between the two assays
[13]. The group however found the sensitivity index to
be the same for the two methods, suggesting that al-
though statistically significant differences do exist be-
tween the two assays, they are likely not biologically
significant[13].
Figure 3 shows the trend in in vitro responses of
Ghanaian P. falciparum isolates to chloroquine between
1990 and 2012. Resistance to chloroquine in vitro in-
creased from 1990 to an all-time high in 2004 and de-
creased significantly in 2012. Figure 4 (a-e) shows the
comparison of IC50 value of some of the popularly used
anti-malarial drugs in Ghana before the change in treat-
ment policy (2004) and the current report (2012). There
was a drastic reduction in IC50 values for chloroquine
determined in 2012 compared with that of 2004: more
than 50% decrease in the pooled national GM IC50
values between the two dates. Compared to the data
from the 2004 survey, the current results showed a mod-
erate increase in GM IC50 value for artesunate and a
high increase for quinine and mefloquine.
The level of correlation between the IC50s of some of
the anti-malarial drugs studied per sentinel site is shown
in Additional file 2: Table S2. A p-value of <0.05 was
considered as the threshold indicative of a statistically
significant correlation. Significant correlation was found
among the following pairs of drugs: amodiaquine versus
quinine (at Cape Coast); artemether versus dihydroarte-
misinin (at Cape Coast and Hohoe); chloroquine versus
quinine (at Hohoe); amodiaquine versus mefloquine (at
Hohoe); mefloquine versus quinine (at Navrongo).
To ensure that the reagents or drugs used in this study
maintained their quality throughout the study period,
3D7 and DD2 clone of P. falciparum was tested fort-
nightly against known drugs and the IC50 values ob-
tained compared with universally acceptable values for
the drugs.
Discussion
In vitro assessment of the susceptibility of malaria para-
sites to drugs remains an important component of anti-

































































































































































































Figures 2 Scatter plots of GMIC50 values determined for test antimalarial drugs. a-e are Plots of IC50 values determined from test of
susceptibility of P. falciparum clinical isolates to some popular anti-malarial drugs used in Ghana. The isolates were collected from three sentinel
sites in the country shown as red for Hohoe, yellow for Navrongo and purple for Cape Coast. The olive green lines on each graph indicate the
IC50 threshold points discriminative for resistance to the drug.
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tion that complements clinical assessment of drug efficacy.
The SYBR Green1 method of assessing the outcome ofthe in vitro drug test was revalidated and used to assess
the responses of P. falciparum clinical isolates to a panel
of 12 anti-malarial drugs in Ghana. To the best of



















Figure 3 Trends in chloroquine resistance in vitro in Ghana.
Trends in resistance of Ghanaian P. falciparum isolates to
chloroquine in vitro from 1990 through 2012 [15,28,29]. The number
of isolates assessed was 195, 64, 57, and 141 for the year 1990, 2001,
2004 and 2012 respectively. NB: the current report is shown in the
chart as 2012.
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method in Ghana and the reported assertion that it is
easy to use, reliable and cheaper could be affirmed. All
the components of ACT currently used in Ghana as
well as quinine and the previous first-line anti-malarial
drug, chloroquine were among the test drugs.
Compared with findings from a similar survey con-
ducted in 2004 [15], the overall resistance to chloroquine
determined in this study dropped drastically from 56 to
13.5%. A pooled national GM IC50 of chloroquine was
also observed to have decreased by more than 50% com-
pared to the 2004 value. These observations are consist-
ent with reports from East African countries, Malawi
and Kenya, indicating the return of chloroquine-sensitive
isolates following a similar official withdrawal of the drug
[30-32]. It also confirms an observation made in a study
conducted in France using isolates collected from
returning visitors from Senegal, Mali, Ivory Coast, and
Cameroon [33]. The large improvement in the efficacy
of chloroquine observed in the present study is im-
portant as it seems to reflect the real situation on the
ground. Indeed, this gives credence to recent finding
in Ghana indicating a significant decline in the preva-
lence of P. falciparum chloroquine-resistant transporter
gene (pfcrt) codon76 mutant allele (T76) and P. falciparum
multidrug-resistant gene (pfmdr1) codon86 mutant allele
(Y86) in the country [34]. Prevalence of pfcrt T76 muta-
tion has been associated with clinical chloroquine resist-
ance and represents a good indicator of the parasite’s
intrinsic resistance to the drug [35,36]. Additionally,
single nucleotide polymorphisms (SNPs) in the pfmdr1
on chromosome 5 which encodes a P-glycoprotein
homologue-1 multi-drug resistant transporter is asso-
ciated with enhanced efflux of the drug from resistant
parasites [37]. Association of chloroquine resistancewith pfmdr1 Y86 has been reported in many genetic
studies including one carried out in Ghana by the
group of Koram [38,39]. Eight years have elapsed
since chloroquine was replaced with ACT as the first-
choice anti-malarial drug in Ghana. It is, therefore,
likely that the withdrawal of chloroquine from use
over these years might have caused a decrease in drug
pressure with a consequent decline of chloroquine-
resistant strains.
Currently, AA is one of the officially recommended
ACT selected for treatment of uncomplicated malaria in
Ghana. The combination is also used for the treatment
of uncomplicated malaria in the second and third tri-
mester of pregnancy and is recommended for the assisted
home management of malaria in Ghana [40]. Although all
the isolates tested in this study appear to be sensitive to
artesunate, of grave concern is the increased pooled na-
tional GM IC50 value measured in this study compared
with that of 2004. This observation suggests an emerging
population of malaria parasites with tolerance for higher
concentrations of artesunate. One explanation could be
selective drug pressure since ACT is now the first line of
therapy for uncomplicated malaria. However, another pos-
sible explanation may be that artesunate is being used
inappropriately in the country thus facilitating the de-
velopment of ‘low level resistance’ by malaria parasites.
Published data by Kwansa-Bentum and colleagues con-
firms the indiscriminate use of artesunate monother-
apy for the treatment of malaria in Ghana [41]. The
consequences of continuation of this practice are obvi-
ous. There is the need to adhere strictly to the current
national treatment guidelines which are in conformity
with the WHO guidelines as endorsed by the World
Health Assembly [42-44]. Recently, a new method for
the assessment of the response of P.falciparumin to
the artemisinins in vitro was developed. This is in re-
sponse to reports suggesting that artemisinin resistant
parasites tolerate high levels of the drug by exiting dor-
mancy and resuming growth at a greater rate than sus-
ceptible parental strains [45]. This situation makes it
difficult to evaluate the in vitro activity of the artemisi-
nin derivatives by standard tests. In the light of this, a
new method called ‘the Ring-stage Survival Assay
(RSA)’ which is supposed to adequately measure P. fal-
ciparum resistance to the aremisinins was developed
and published by Witkowski and co-workers [46]. With
regard to amodiaquine, there was no significant change in
the GM IC50 value determined in this study compared to
the 2004 value. However, a few of the P. falciparum iso-
lates were observed to be resistant to the drug in vitro.
Amodiaquine is chemically related to chloroquine, and it
is not extensively used in Ghana for monotherapy. The
high susceptibility of the parasite to amodiaquine ob-














































































Figures 4 Comparison between GMIC50 values of antimalarial drugs. The GM IC50 values of some selected anti-malarial before (2004) and
eight years after (2012) the change in malaria treatment policy in Ghana were compared. The comparison is shown in a-e of the figure for chloroquine,
amodiaquine, quinine, artesunate and mefloquine respectively. The error bars are the standard error of the mean.
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earlier and/or the switch from amodiaquine monother-
apy to AA combination therapy: the combination might
have offered protection to amodiaquine and precipitated
the improvement or stability of amodiaquine and chloro-
quine susceptibility. The stability in potency justifies the
continuous use of amodiaquine as a component of the of-
ficial ACT.
Artemether-lumefantrine combination was recommended
as an alternative for the treatment of uncomplicated malariain Ghana following reports of adverse reaction to AA [47].
All the P. falciparum isolates tested in this study were sus-
ceptible to artemether with an overall national GM IC50
value of 4.5 nM. The isolates also responded to lumefantrine
with a pooled national GM IC50 value of 5.2 nM. Based on
the literature cut-off for resistance, only one isolate showed
resistance to lumefantrine. There is no baseline in vitro data
on these two drugs in Ghana hence the changes that might
have occurred in their efficacy since the change in the treat-
ment policy could not be discussed. However, compared
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tries, the IC50 values of the drugs measured in the present
study are much lower.
Combination of dihydroartemisinin and piperaquine is
another form of ACT recommended for the treatment
of uncomplicated malaria in Ghana. All the isolates
assessed in this study were sensitive to dihydroartemisi-
nin. Since the former is the active metabolite of artesu-
nate, the result was not surprising. No correlation
indicative of cross-resistance was found between arte-
sunate and dihydroartemisinin. Resistance level of
piperaquine could not be ascertained in this study
due to the unavailability of literature cut-off IC50
value indicative of resistance to the drug.
A geometric mean IC50 value of 107.2nM determined
for quinine is more than double that reported in 2004.
Furthermore, unlike in 2004, some of the isolates tested
in this study were resistant to the drug. Quinine is an
important anti-malarial drug in Ghana as it remains the
drug of choice for the management of complicated mal-
aria and in the event of ACT treatment failure. Oral
quinine or a combination of oral quinine and clindamy-
cin is also the recommended drug for the management
of uncomplicated malaria during the first trimester of
pregnancy in Ghana [47]. Since this drug is not used on
a regular basis in Ghana, a clear explanation for the de-
crease in parasite susceptibility to the drug observed
in vitro is not easy to come by. However, it is note-
worthy that in surveys of drug quality in sub-Saharan
Africa, quinine has often been found to be sub-standard,
including samples with low concentrations of active in-
gredient [48]. The use of sub-standard drug is likely to
jeopardize the efficacy of the anti-malarial drug.
Mefloquine and atovaquone are recommended drugs
for non-immune travellers for chemoprophylaxis. Even
though the pooled GM IC50 determined in this study for
mefloquine was far below the cut-off value discrimina-
tive for resistance, about 16.6% of the P. falciparum iso-
lates assessed were resistant to the drug. Compared with
the level observed in the 2004 study, the IC50 measured
here is over five-fold increase. Mefloquine, which be-
longs to the amino-alcohol class, is not used much in
Ghana, hence drug pressure could not explain the in-
crease in resistance. However, since some in vitro studies
have demonstrated an inverse relationship between the
responses of chloroquine and the amino-alcohols [49,50]
this phenomenon could best explain the observation. All
the P. falciparum isolates tested in this study were sensi-
tive to atovaquone.
Tafenoquine, an 8-aminoquinoline anti-malarial drug,
which was recently introduced to the world market, rep-
resents a potential alternative to standard agents for the
prevention and radical cure of malaria [51]. In the ab-
sence of an available literature cut-off value indicative ofresistance, the GM IC50 value of 93.6 nM obtained in
this study was compared with those determined in other
countries. The IC50 values reported from other countries
range from 0.9 to 9.7 μM in Djibouti, 0.6 to 33.1 μM in
Gabon, and 0.5 to 20.7 μM in Senegal [52]. Compared
with these values, the pooled national GM IC50 value of
93.6 nM determined in this study is relatively low and
implies that Ghanaian P. falciparum isolates are highly
sensitive to the drug.
The anti-malarial activity of tetracycline and its deriva-
tives has been demonstrated in vitro and in vivo [53-55].
Currently doxycycline is recommended as chemoprophy-
laxis to non-immune travellers to some disease-endemic
countries of the world. Doxycycline is also used generally
as an antibiotic for the management of a variety of infec-
tion such as Lyme disease, acne, urinary tract infections,
and pneumonia, among others. However, information on
its use in Ghana both as an anti-malarial drug or antibiotic
is scanty. In the present study, doxycycline had the least
effect on the clinical isolates tested, showing a resistance
level of above 20%. The observed high resistance to the
drug could be explained in terms of its mechanism of ac-
tion. A study by Dahl and Rosenthal showed that the
pharmacological concentration of the drug was relatively
inactive against the parasites initially but exerted a delayed
death effect, in which the progeny of treated parasites
failed to complete erythrocytic development [56]. The re-
port further indicated that the drug does not alter the dis-
tribution of apicoplasts in developing parasites but affects
their progeny. This implies that a longer period of expos-
ure is required to achieve maximum effect of doxycycline.
Since in the present study the parasites were cultured for
only 72 hours, the duration of the culture may be insuffi-
cient and could be the reason for the slow anti-malarial
action of doxycycline observed in this study. An extended
time of incubation to 96 hours would have ensured ad-
equate effect of the drug on the parasite and would have
presented a better picture of the Ghanaian P. falciparum
isolate’s susceptibility to doxycycline.
An important observation made in this study was that
the P. falciparum isolates from Cape Coast exhibited
higher IC50 values compared to those from the other
sites. Environmental and socio-economic factors could
be possible reasons for this observation. The site in Cape
Coast receives most of its clients from communities with
poor infrastructural development. The presence of stag-
nant water in these communities might contribute
greatly to mosquito breeding and an increase in mal-
aria transmission. This situation is likely to lead to in-
creased anti-malarial use in this area. Indeed, an
unpublished investigation by the group of Johnson
Boampong (University of Cape-Coast, Ghana) con-
firmed the indiscriminate use of anti-malarial drugs in
the study area (Kwame Asare Kumi, pers comm). This
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with a consequent selection and nurturing of resistant
parasites.
Cross-resistance could be said to occur when a drug
confers resistance to other drugs that have similar mode
of action or belong to the same chemical group. Cross-
resistance may complicate anti-malarial drug resistance,
and its existence is worth investigating. A positive cor-
relation between the responses to two anti-malarial
drugs suggests an in vitro cross-resistance but not neces-
sarily confer cross-resistance in vivo. In the present
study, the existence of cross-resistance among some of
the test drugs was ascertained. A positive correlation
was found between the IC50 values for: amodiaquine and
quinine, artemether and dihydroartemisinin, chloroquine
and quinine, amodiaquine and mefloquine, and meflo-
quine and quinine. All the observed significant correla-
tions were limited to one site except that between
artemether and dihydroartemisinin where it was ob-
served in two of the three sites surveyed. It is worth not-
ing that a significant correlation between two drugs
tested in vitro doesn’t necessary mean a cross resistance
exist among them. For a correlation to imply that two
compounds share common mechanisms of action or re-
sistance, which could induce cross-resistance, the coeffi-
cient of determination (r2) must be high. In this study,
the r2 values of the drugs showing significant correlation
were too low to suggest a strong cross-resistance be-
tween them. Contrary to expectation, no positive correl-
ation was observed between artesunate and artemether
or dihydroartemisin. A possible explanation for this ob-
servation could be the usage of a single ACT in the
study areas: artesunate amodiaquine combination is the
most widely used ACT in these communities. Significant
correlation between some of these drugs may be explained
in part by close resemblance in chemical structures. It
must be emphasized that clinical and epidemiological sig-
nificance or implications of the correlation between some
of the anti-malarial drugs observed in this study will be
difficult to decipher.
Delayed clearance of P. falciparum isolates with ACT
has recently been reported [8]. The emergence of P. fal-
ciparum resistance to artemisinin derivatives is of urgent
public health concern, which could considerably slow
down the global effort to reduce the malaria burden. In
the absence of an effective malaria vaccine, steps must
be taken to protect the artemisinin derivatives. In the
light of this, the WHO has launched the Global Plan for
Artemisinin Resistance Containment (GPARC) aimed at
avoiding the spread of resistance from the area of first
report of resistance to other disease-endemic zones [57].
In Ghana, various measures have been taken by the
NMCP to avoid the emergence of drug resistance to
ACT; sentinel sites have been set up across the countryto monitor the efficacy of ACT. However, with the ob-
servations made in this study, the need to adopt a more
aggressive approach must be considered. The NMCP
needs to launch a more vigorous national campaign
against improper use of the artemisinin derivatives. Equally
important is drug quality: steps must be taken to eliminate
counterfeit ACT and reduce sub-standard manufacturing
with lower concentration of artemisinin content. The en-
tire pharmaceutical distribution modes and drug supply
chains that impact directly on drug use must be purged to
ensure the supply of good quality drugs and the total en-
forcement of the ban on certain anti-malarial drugs such
as chloroquine, or cessation of practices such as the use of
the artemisinin derivatives as monotherapy. With the valid-
ation and subsequent use of the SYBR Green method in
Ghana, continuous assessment of the susceptibility of
P. falciparum to anti-malarial drugs in the country
must be encouraged in order to make available to the
NMCP supportive data that will allow prediction of
emerging resistant strains of parasites in the country.Conclusion
Given the lack of robust molecular markers predictive of
anti-malarial resistance for the artemisinins and the huge
cost in conducting in vivo efficacy study, the in vitro
method of assessment of the artemisinins and other anti-
malarial drugs is warranted. The in vitro method was
successfully used to assess the sensitivity of Ghanaian P.
falciparum isolates to 12 anti-malarial drugs. Although
frank resistance to artesunate was not observed, a con-
cerning trend of increasing GMIC50 since the introduc-
tion of ACT was noticed. This situation warrants
continuous monitoring of ACT. On the other hand,
chloroquine appears to have regained a greater propor-
tion of its efficacy after being out of use as first-line
drug for eight years.Additional files
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